Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Blood Test-Based Method Diagnoses Bile Acid Diarrhea from Single Sample

By LabMedica International staff writers
Posted on 07 Jul 2023

Bile acid malabsorption, also known as bile acid diarrhea, is a type of chronic diarrhea characterized by more than ten sudden episodes of diarrhea in a day. While the condition isn't life-threatening, it can severely disrupt a patient's day-to-day life, particularly their social activities, and can be significantly debilitating. Often, most instances of bile acid diarrhea are either diagnosed at an advanced stage or go undetected entirely, resulting in patients enduring this condition for several years before receiving a diagnosis. Now, a new study has discovered innovative methods for diagnosing bile acid diarrhea and identifying the most effective treatment tailored for each patient.

A team of researchers at University of Copenhagen (Copenhagen, Denmark) has devised a new approach for diagnosing bile acid diarrhea using a simple blood sample. This new technique focuses on blood molecules referred to as metabolites. A blood sample comprises several distinct metabolites. Among the nearly 1,300 identified metabolites, about a handful can be utilized to diagnose bile acid diarrhea. The metabolites in bile acid diarrhea patients form a specific pattern, making them easily identifiable.

For their research, the team examined blood samples from 50 patients and quickly observed that the samples – and by extension, the patients – could be segregated into two groups. Following this, the patients participated in a randomized clinical study where the researchers explored the effects of two different treatments: the standard treatment with bile acid sequestrant colesevelam and a novel treatment with liraglutide, typically used to manage type 2 diabetes and severe obesity. The clinical study revealed that while colesevelam treatment alleviated the bile acid diarrhea symptoms in 50% of the patients, liraglutide treatment proved successful for 77% of the patients.

“What is interesting is that the metabolites in the patients’ blood divided them into two groups: one that responds well to colesevelam and one that responds well to liraglutide. This suggests that we should be able to say which treatment is the most effective by analyzing the patient’s blood at the time of diagnosis,” said Professor Jesper Bøje Andersen from the Biotech Research & Innovation Centre.

Related Links:
University of Copenhagen 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.